Vamsi Mootha is an Investigator of the Howard Hughes Medical Institute and directs a laboratory based at Massachusetts General Hospital. He is also Professor of Systems Biology and Medicine at Harvard Medical School and a Senior Associate Member of the Broad Institute.

Dr. Mootha’s research is focused on mitochondria, often termed the “powerhouses of the cell.” Dr. Mootha’s group has utilized tandem mass spectrometry, computation, and biochemistry to characterize the mitochondrial proteome, which now serves as a molecular blueprint for clinical and systematic studies of mitochondria. Dr. Mootha and his colleagues have used this inventory to discover the mitochondrial calcium uniporter, a major channel of communication between mitochondria and the rest of the cell. He collaborates extensively with clinicians and researchers throughout the world, and together they have elucidated more than one dozen disease genes that underlie severe, metabolic diseases. His team has developed a number of computational tools that are used widely by the community.

Dr. Mootha received his undergraduate degree in mathematical and computational science at Stanford University and his MD in 1998 from Harvard Medical School in the Harvard-MIT Division of Health Sciences and Technology. He subsequently completed his internship and residency in internal medicine at Brigham and Women’s Hospital in 2001, after which he completed postdoctoral fellowship training at the Whitehead Institute.

Dr. Mootha has received a number awards, including a Macarthur “Genius Grant,” and is an elected member of the National Academy of Sciences.

Joshua Rabinowitz is Professor of Chemistry and Integrative Genomics at Princeton University. He is a Member of the Rutgers Cancer Institute of New Jersey and the Lewis-Sigler Institute at Princeton University.

Dr. Rabinowitz’s lab studies metabolism from the system biology perspective. His group develops methods that combine mass spectrometry, isotope tracers, and mathematical modeling to quantitate metabolic flux. Using these methods, Dr. Rabinowitz attempts to understand basic principles of metabolic flux control. His lab has found that most enzyme active sites are saturated, with competition between metabolites determining enzyme activity. It is now combining metabolomics with proteomics to investigate the relative importance of active site competition, allostery, and enzyme concentrations in overall metabolic regulation. Dr. Rabinowitz’s lab is also interested in identifying the contributions of different pathways to producing key high-energy cofactors, such as ATP, NADPH, and activated one-carbon donors. Recently, it identified an unexpected tie between two of these cofactor systems, with folate metabolism playing a significant role in redox homeostasis. The lab collaborates broadly, with one notable collaboration having led to discovery of the oncometabolite 2-hydroxyglutarate. Methods developed in the lab are widely used in the cancer metabolism community.

Dr. Rabinowitz received his undergraduate degrees in mathematics and chemistry from the University of North Carolina-Chapel Hill with highest honors. He subsequently completed his MD/PhD at Stanford University in the laboratory of Harden M. McConnell, graduating in 2001. Thereafter, Dr. Rabinowitz founded Alexza Pharmaceuticals, inventing the Adasuve inhaler (now FDA-approved for treatment of acute agitation). In 2004, he joined the faculty of Princeton University. There he has received several honors, including the Beckman Young Investigators Award, the NSF Career Award, and the Agilent Thought Leader Award.

David Sabatini is a Member of the Whitehead Institute for Biomedical Research, Senior Associate Member of The Broad Institute, and Member of the Koch Institute for Integrative Cancer Research at MIT, as well as a Professor of Biology at the Massachusetts Institute of Technology. He is also an Investigator of the Howard Hughes Medical Institute.

Dr. Sabatini and his lab at the Whitehead Institute study the basic mechanisms that regulate cell growth, the process whereby cells and organisms accumulate mass and increase in size. These pathways are often deranged in human diseases, such as diabetes and cancer. A major focus of the lab is a cellular system called the Target of Rapamycin (TOR) pathway, a major regulator of growth in many eukaryotic species. Work in Dr. Sabatini’s lab has led to the identification of many components of the pathway and to an understanding of their cellular and organismal functions. Dr. Sabatini is also interested in the role of metabolism in cancer and in the mechanisms that control the effects of dietary restriction on tumorigenesis. In addition to the work on growth control and cancer, Dr. Sabatini’s lab has developed and is using new technologies that facilitate the analysis of gene function in mammalian cells. The lab developed ‘cell-based microarrays’ that allow one to examine the cellular effects of perturbing the activity of thousands of genes in parallel. Dr. Sabatini is a founding member of The RNAi Consortium (TRC) of labs in the Boston area that is developing and using genome-scale RNA interference (RNAi) libraries targeting human and mouse genes.

Dr. Sabatini received his BS from Brown University magna cum laude and his MD/PhD from Johns Hopkins University in 1997. He completed his thesis work in the lab of Dr. Solomon H. Snyder in the Department of Neuroscience. Later in the same year, Dr. Sabatini was appointed a Whitehead Fellow at the Whitehead Institute for Biomedical Research. This was followed in 2002 by a dual appointment as a Member at the Whitehead Institute and Assistant Professor of Biology at the Massachusetts Institute of Technology. Dr. Sabatini has received a number of distinctions, including being named a W. M. Keck Foundation Distinguished Young Scholar, a Pew Scholar, and a TR100 Innovator, as well as the 2009 Paul Marks Prize for Cancer Research, the 2012 Earl and Thressa Stadtman Scholar Award from ASBMB, the 2013 Feodor Lynen Award from Nature, and most recently the 2014 NAS Award in Molecular Biology.

Julian Adams is President, Research and Development at Infinity Pharmaceuticals. Dr. Adams is responsible for the full spectrum of Infinity’s drug discovery, preclinical and clinical development strategy, and regulatory affairs activities. Prior to joining Infinity in 2003, Dr. Adams was the Senior Vice President, Drug Discovery and Development at Millennium Pharmaceuticals. In this capacity, he had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy. He previously served as Senior Vice President, Research and Development for LeukoSite and as a member of the founding management team, Executive Vice President of Research and Development, and a member of the Board of Directors for ProScript, Inc. Earlier in his career, Dr. Adams served in various positions, including Director, Medicinal Chemistry at Boehringer Ingelheim, where he successfully discovered the drug Viramune® (nevirapine) for HIV.

Dr. Adams has received many awards, including the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation. Dr. Adams is an inventor of more than 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals. He is the editor of Proteasome Inhibition in Cancer Therapy, published in July 2004.

Dr Adams is on the Board of Directors of Warp Drive Bio and the Princess Margaret Cancer Foundation and is on the scientific advisory boards of Cleave Biosciences and Stand Up to Cancer.

Dr. Adams received his B.S. from McGill University and his Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. He also received the degree of Doctor of Science, honoris causa, from McGill University in 2012.

Robert Copeland, PhD, is President of Research and Chief Scientific Officer at Epizyme, Inc., where he leads research and the scientific vision. Previously, he served as Vice President of Cancer Biology, Oncology Center of Excellence in Drug Discovery, at GlaxoSmithKline. He has also held scientific positions at Merck Research Laboratories, DuPont-Merck and Bristol-Myers Squibb and a faculty position at the University of Chicago, Pritzker School of Medicine.

Dr. Copeland received his B.S. in chemistry from Seton Hall University, his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology. His research interest is in elucidating the determinants of drug recognition by their biological targets, and the use of this information in the discovery and design of new medicines. A common theme throughout his research has been the role of protein dynamics in drug-target interactions.

Dr. Copeland has contributed to drug discovery and development efforts across a wide range of therapeutic areas leading to 17 drug candidates entering human clinical trials. These include the cancer drugs Tafinlar (Dabrafenib), Foretinib, Afuresertib and Mekinist (Trametinib) and the antibiotic Altabax (Retapamulin). Dr. Copeland has published more than 200 scholarly publications, holds ten issued U.S. patents and has authored five books in the areas of protein science and enzymology.

George Q. Daley is the Samuel E. Lux IV Professor of Hematology/Oncology, Director of the Stem Cell Transplantation Program at Children’s Hospital Boston, Professor of Biological Chemistry and Molecular Pharmacology and Pediatrics at Harvard Medical School, and an investigator of the Howard Hughes Medical Institute. He is a founder and adviser to numerous successful biotechnology start-ups, and his past work on the role of BCR/ABL in chronic myeloid leukemia paved the way for the development of imatinib (Gleevec®)

Dr. Daley’s research exploits mouse and human disease models to identify mechanisms that underlie cancer and blood disease. He received his bachelor’s degree magna cum laude from Harvard University (1982), a PhD in biology from MIT (1989), and MD from Harvard Medical School summa cum laude (1991). Dr. Daley served as President of the International Society for Stem Cell Research (ISSCR) from 2007 to 2008, led the special task forces that produced the ISSCR Guidelines for Stem Cell Research (2006) and Clinical Translation (2008), and is currently the ISSCR Clerk.

Dr. Daley has been elected to the Institute of Medicine of the National Academies, American Society for Clinical Investigation, American Association of Physicians, American Pediatric Societies, American Academy of Arts and Sciences, and American Association for the Advancement of Science, and has received the NIH Director’s Pioneer Award, the Judson Daland Prize from the American Philosophical Society, the E. Mead Johnson Award from the American Pediatric Society, and the E. Donnall Thomas Prize from the American Society for Hematology.

Keith Flaherty is director of the Henri and Belinda Termeer Center for Targeted Therapies at the Massachusetts General Cancer Center and Associate Professor of Medicine at Harvard Medical School. Dr. Flaherty’s research and clinical focus is therapies for melanoma, with a particular expertise in targeted therapies.

Dr. Flaherty obtained his undergraduate degree from Yale University in 1993 and an MD from Johns Hopkins University in 1997. He completed his internship in medicine, followed by a residency in medicine, at Brigham and Women’s Hospital (Harvard Medical School) in Boston. He went on to complete a fellowship in Medical Oncology at the Hospital of the University of Pennsylvania.

The goal of Dr. Flaherty’s group is to understand the molecular and clinical consequences of inhibiting oncogenes and oncogenic pathways in melanoma with the aim of establishing individual approaches as therapies and constructing rational combination therapies.  Dr. Flaherty led the early clinical development of vemurafenib and trametinib (now FDA approved), and the dabrafenib/trametinib combination. He has been the principal investigator of many clinical trials, including first-in-human trials of novel targeted therapies, and two NCI cooperative group trials. He has authored more than 150 research articles, abstracts and reviews in the peer-reviewed literature, including 3 first-author New England Journal of Medicine papers. He serves as a senior editor for Clinical Cancer Research and a member of the editorial boards for Cancer Discovery, Journal of Clinical Oncology, Cancer, and Pigment Cell and Melanoma Biology.

Michael Gilman is a scientist, general manager, biotech executive, and entrepreneur, currently serving as a Venture Partner at Atlas Venture and Chief Executive Officer of Padlock Therapeutics. He previously served as Raze acting CEO during its formation. His previous position was Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company’s development programs through clinical proof-of-concept. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-backed company focused on fibrosis and organ failure, where Dr. Gilman was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, Dr. Gilman served as Executive Vice President, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. Dr. Gilman was a postdoctoral fellow at the Whitehead Institute. He holds a PhD in Biochemistry from University of California, Berkeley, and a SB in Life Sciences from Massachusetts Institute of Technology.
Karen Vousden received her BSc and PhD in Genetics from Queen Mary College at the University of London working with Lorna Casselton, followed by postdoctoral fellowships with Chris Marshall at the Institute of Cancer Research in London and Douglas Lowy at the National Cancer Institute in the USA. Following her fellowships, she became head of the human papillomavirus group at the Ludwig Institute for Cancer Research in London before moving back to the NCI in 1995, where she was Director of the Molecular Virology and Carcinogenesis Section at the ABL-Basic Research programme. Dr. Vousden later served as Chief of the Regulation of Cell Growth Laboratory. She took up her current position as Director of the Beatson Institute in 2002.

Dr. Vousden’s own research focuses on the tumour suppressor protein p53, which plays an important role in cancer prevention. Her lab is interested in understanding the signals that induce p53 and the functions of p53 that contribute to its ability to prevent cancer progression. Ultimately, they hope to be able find ways to use an understanding of the p53 pathway for cancer therapy.

Dr. Vousden has been elected as a fellow of the Royal Society, the Royal Society of Edinburgh, EMBO, the Academy of Medical Sciences, the European Academy of Sciences and the American Association for the Advancement of Science. She has also received honorary DScs from the Universities of London and Strathclyde. Dr. Vousden’s awards include the Tenovus Gold Medal, the Sir Frederick Gowland Hopkins Medal, the Royal Medal from the Royal Society of Edinburgh and she was made a Commander of the British Empire for services to clinical science. She is presently on the Board of Directors of the AACR and on the EMBO Council.